Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma 900Lymphoma, Non-Hodgkin 685Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Lymphoma, Follicular 516Hodgkin Disease 442Lymphoma, Mantle-Cell 421Leukemia 410Lymphoma, B-Cell, Marginal Zone 289Burkitt Lymphoma 285Recurrence 277Leukemia, Myeloid, Acute 276Multiple Myeloma 250Myelodysplastic Syndromes 237Waldenstrom Macroglobulinemia 187Lymphoma, B-Cell 179Lymphoma, Large-Cell, Immunoblastic 153Lymphoma, T-Cell, Cutaneous 143Leukemia, Myelogenous, Chronic, BCR-ABL Positive 127Lymphoma, T-Cell, Peripheral 123Mycosis Fungoides 118Myeloproliferative Disorders 112Lymphoma, Large-Cell, Anaplastic 107Dendritic Cell Sarcoma, Interdigitating 103Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 102Neoplasms 98Lymphoma, Extranodal NK-T-Cell 96Hematologic Neoplasms 96Sezary Syndrome 94

Interventions

Vincristine 2Methotrexate 2Mercaptopurine 2Hydrocortisone 2Cytarabine 2prednylidene 1pegaspargase 1merphos 1hydrocortisone hemisuccinate 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1blinatumomab 1azathiopurine 1auricularum 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Prednisolone 1Nivolumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Epirubicin 1Dexamethasone 1Daunorubicin 1Cyclophosphamide 1Calcium Dobesilate 1Biopsy 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Down Syndrome × Lymphoid × Clear all
NCT03286634 2026-05-11

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

National Hospital Organization Nagoya Medical Center

Phase 2 Active not recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Down Syndrome, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡